Geron (GERN) Depreciation & Amortization (CF) (2017 - 2026)
Geron (GERN) posted Depreciation & Amortization (CF) of $134000.0 for Q1 2026, up 54.02% sequentially from $87000.0 in Q4 2025, and up 2.29% YoY from $131000.0 in Q1 2025.
Geron (GERN) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Geron has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $134000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 2.29% year-over-year to $134000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $477000.0 (down 15.72% YoY) and the FY2025 annual result came in at $474000.0, down 13.19% from the prior year.
- Depreciation & Amortization (CF) climbed to $134000.0 in Q1 2026 per GERN's latest filing, from $87000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $262000.0 in Q2 2024 and troughed at $31000.0 in Q3 2024.
- A 5-year average of $110823.5 and a median of $111000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) plunged 71.3% in 2024, then surged 312.9% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $80000.0 in 2022, then soared by 42.5% to $114000.0 in 2023, then advanced by 24.56% to $142000.0 in 2024, then tumbled by 38.73% to $87000.0 in 2025, then soared by 54.02% to $134000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $134000.0, $87000.0, and $128000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 136,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 136,000.00 |
| Jun 30, 2026 | 136,000.00 |
| Mar 31, 2026 | 134,000.00 |
| Mar 31, 2026 | 134,000.00 |
| Dec 31, 2025 | 87,000.00 |
| Dec 31, 2025 | 87,000.00 |
| Sep 30, 2025 | 128,000.00 |
| Sep 30, 2025 | 128,000.00 |
| Jun 30, 2025 | 128,000.00 |
| Jun 30, 2025 | 128,000.00 |
| Mar 31, 2025 | 131,000.00 |
| Mar 31, 2025 | 131,000.00 |
| Dec 31, 2024 | 142,000.00 |
| Dec 31, 2024 | 142,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 262,000.00 |
| Jun 30, 2024 | 262,000.00 |
| Mar 31, 2024 | 111,000.00 |
| Mar 31, 2024 | 111,000.00 |